Exhibit 99.1 Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update • Presented data from EVANGELINE study showing 100% disease control rate at 24-weeks • Initiated study evaluating (Z)-endoxifen in combination with abemaciclib (VERZENIO®) • Ended first quarter 2024 with $84.0 million of cash and cash equivalents and no debt SEATTLE, May 13, 2024— Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company") today announced financial results for the fiscal qu ...

Presented data from EVANGELINE study showing 100% disease control rate at 24-weeks Initiated study evaluating (Z)-endoxifen in combination with abemaciclib (VERZENIO®)Ended first quarter 2024 with $84.0 million of cash and cash equivalents and no debt SEATTLE, May 13, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced financial results for the fiscal quarter ended March 31, 2024, and provides an update on recent company developments. Atossa is a clin ...

Under-the-radar penny stocks can be some of the most rewarding investments on the market. Look at ACADIA Pharmaceuticals (NASDAQ:ACAD), for example. Back in 2011, the biotech was just developing its treatment of Parkinson’s disease psychosis and traded at just 70 cents. By 2015, it was at $51.24.Or, look at Advanced Micro Devices (NASDAQ:AMD). In 2015, it traded at about $1.99. Today, thanks to the artificial intelligence and semiconductor boom, it hit a hit of $214.81.Each had incredible growth stories tha ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced its support of new guidelines released by the U.S. Preventive Services Task Force (USPSTF) recommending that women begin breast cancer screening starting at age 40. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The updated guidelines recommend women undergo bie ...

SEATTLE, April 29, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced an expanded research agreement with Weill Cornell Medicine to explore the potential synergy between antibody drug conjugates (ADCs) and (Z)-endoxifen. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The expanded research agreement with Weill Cornell will build ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

SEATTLE, April 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") and Quantum Leap Healthcare Collaborative™ today announced the initiation of a new study to evaluate Atossa's proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO®), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company, in women with ER+/HER2- breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of si ...

Atossa Therapeutics, Inc. (ATOS) recently announced promising safety and efficacy data from the company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial.(Z)-endoxifen is being assessed as a neoadjuvant treatment for premenopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer as part of the EVANGELINE research.More on the EVANGELINE StudyIn Phase 2 EVANGELINE study, participants are likely to recei ...

SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at the Noble Capital Markets Emerging Growth Healthcare Conference on Wednesday, April 17 at 9:00 am ET. The presentation will be available virtually and members of the Company's leadership team will be available for one-on-one meetings with registered investors of the conference. Atossa is a clinical stage biopharma ...